Form 8-K - Current report:
SEC Accession No. 0000950170-24-122300
Filing Date
2024-11-06
Accepted
2024-11-06 16:10:11
Documents
13
Period of Report
2024-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rgnx-20241106.htm   iXBRL 8-K 40525
2 EX-99.1 rgnx-ex99_1.htm EX-99.1 246168
3 GRAPHIC img101737798_0.jpg GRAPHIC 14325
  Complete submission text file 0000950170-24-122300.txt   435962

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgnx-20241106.xsd EX-101.SCH 25018
15 EXTRACTED XBRL INSTANCE DOCUMENT rgnx-20241106_htm.xml XML 4739
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37553 | Film No.: 241431007
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)